Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company focused on developing cancer therapies, reported no revenue for the three and nine months ended September 30, 2024, consistent with the same periods in 2023. The company recorded a net loss of $986,030 for the third quarter of 2024, a slight improvement from a net loss of $1,018,760 in the same quarter of the previous year. For the nine months ended September 30, 2024, the net loss was $2,968,271, compared to $4,054,774 for the same period in 2023, reflecting a reduction in losses due to decreased operational costs.
Total costs and expenses for the third quarter of 2024 were $983,257, down from $1,024,181 in the prior year. For the nine-month period, total costs decreased to $2,959,292 from $4,064,326 in 2023. The reduction in costs was primarily attributed to a significant decrease in general and administrative expenses, which fell by 31.6% to $2,267,890 for the nine months ended September 30, 2024, compared to $3,315,297 in 2023. Research and development costs for the nine months ended September 30, 2024, totaled $691,402, a decrease from $749,029 in the previous year.
As of September 30, 2024, Lixte had cash and cash equivalents of $1,637,627, a decline from $4,203,488 at the end of 2023. The company’s total assets were reported at $1,695,892, down from $4,308,620 at the end of the previous fiscal year. The accumulated deficit increased to $(51,449,999) from $(48,481,728) at the end of 2023, indicating ongoing financial challenges.
Strategically, Lixte is engaged in several clinical trials for its lead compound, LB-100, which is being tested in combination with other therapies for various cancer types. The company has entered into a Clinical Trial Agreement with the Netherlands Cancer Institute for a Phase 1b trial of LB-100 combined with atezolizumab, which commenced in August 2024. Additionally, the company has faced challenges, including a deficiency letter from Nasdaq regarding its stockholders' equity, prompting a plan to regain compliance by February 2025.
The company has expressed substantial doubt about its ability to continue as a going concern within one year from the issuance of its financial statements, emphasizing the need for additional capital to fund ongoing operations and clinical trials.
About LIXTE BIOTECHNOLOGY HOLDINGS, INC.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.